A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride

Takahiro Maeda, Eiji Kikuchi, Masanori Hasegawa, Toshiyuki Ando, Masashi Matsushima, Kazuyuki Yuge, Yujiro Ito, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We prospectively evaluated erectile function (EF) using the Sexual Health Inventory for Men (SHIM) and the erectile hardness score (EHS) as well as urinary statuses using the International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS) before and 3, 6, and 12 months after a daily treatment with 0.5 mg dutasteride (DUT). Significant improvements were observed in IPSS and OABSS in 98 patients with the DUT treatment, and the effects were similar between 28 patients with potency with baseline SHIM of 8 or greater and 70 severe erectile dysfunction (ED) patients at baseline. In the 28 patients with potency, significant decreases were observed in SHIM and EHS after 3, 6, and 12 months of the DUT treatment, with the severity of ED according to SHIM deteriorating in half of these patients after 12 months of the DUT treatment. Eighteen out of 28 patients (64.3%) with potency at baseline had awareness of the occurrence of ED before the DUT treatment, were younger, and had higher SHIM and EHS just before the DUT treatment than their counterparts. Regular assessments of EF may be needed, especially in younger patients and those with higher levels of EF before the administration of DUT.

Original languageEnglish
Pages (from-to)111-116
Number of pages6
JournalAging Male
Volume19
Issue number2
DOIs
Publication statusPublished - 2016 Apr 2

Keywords

  • Dutasteride
  • Sexual Health Inventory for Men
  • erectile hardness score
  • sexual adverse events
  • urinary status

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride'. Together they form a unique fingerprint.

  • Cite this